ResMed Inc. vs ProShares Ultra Semiconductors — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while ProShares Ultra Semiconductors trades at $99.02 (market cap $2.94B). The key difference: ResMed Inc. is far larger — about 10.8× ProShares Ultra Semiconductors's market cap, and ResMed Inc. pays a 1.16% dividend while ProShares Ultra Semiconductors pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and ProShares Ultra Semiconductors for 29 Days on average.
| RMD | USD | |
|---|---|---|
Market Cap | $31.89B | $2.94B |
Volume | 618,314 | 630,148 |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.88 | $113.53 |
52-Week Low | $182.82 | $43.19 |
Typical Hold Time | 51 Days | 29 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
USD stock trades at $102.77, down 0.96% on the day, with a bullish technical signal driven by strong moving average alignment. The stock shows overbought conditions on shorter-term RSI readings while maintaining positive momentum indicators. Recent corporate actions include a scheduled dividend payment of $0.13 per share for September 2026. Price levels indicate support near $100-$102 and resistance at $103-$105.
The stock's technical strength contrasts with limited fundamental data availability. Investors face uncertainty regarding valuation metrics and profitability measures, requiring careful assessment of upcoming financial disclosures. Near-term price action will likely hinge on market sentiment and technical levels given the current information gap on core business fundamentals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →